Literature DB >> 22858156

Mechanisms of glioma-associated neovascularization.

Matthew E Hardee1, David Zagzag.   

Abstract

Glioblastomas (GBMs), the most common primary brain tumor in adults, are characterized by resistance to chemotherapy and radiotherapy. One of the defining characteristics of GBM is an abundant and aberrant vasculature. The processes of vascular co-option, angiogenesis, and vasculogenesis in gliomas have been extensively described. Recently, however, it has become clear that these three processes are not the only mechanisms by which neovascularization occurs in gliomas. Furthermore, it seems that these processes interact extensively, with potential overlap among them. At least five mechanisms by which gliomas achieve neovascularization have been described: vascular co-option, angiogenesis, vasculogenesis, vascular mimicry, and (the most recently described) glioblastoma-endothelial cell transdifferentiation. We review these mechanisms in glioma neovascularization, with a particular emphasis on the roles of hypoxia and glioma stem cells in each process. Although some of these processes are well established, others have been identified only recently and will need to be further investigated for complete validation. We also review strategies to target glioma neovascularization and the development of resistance to these therapeutic strategies. Finally, we describe how these complex processes interlink and overlap. A thorough understanding of the contributing molecular processes that control the five modalities reviewed here should help resolve the treatment resistance that characterizes GBMs.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22858156      PMCID: PMC3463636          DOI: 10.1016/j.ajpath.2012.06.030

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  100 in total

1.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.

Authors:  Mats Hellström; Li-Kun Phng; Jennifer J Hofmann; Elisabet Wallgard; Leigh Coultas; Per Lindblom; Jackelyn Alva; Ann-Katrin Nilsson; Linda Karlsson; Nicholas Gaiano; Keejung Yoon; Janet Rossant; M Luisa Iruela-Arispe; Mattias Kalén; Holger Gerhardt; Christer Betsholtz
Journal:  Nature       Date:  2007-01-28       Impact factor: 49.962

3.  Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma.

Authors:  Baocun Sun; Danfang Zhang; Shiwu Zhang; Wenzhi Zhang; Hua Guo; Xiulan Zhao
Journal:  Cancer Lett       Date:  2006-09-25       Impact factor: 8.679

Review 4.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.

Authors:  Michele De Palma; Craig Murdoch; Mary Anna Venneri; Luigi Naldini; Claire E Lewis
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

Review 5.  VEGF-A and the induction of pathological angiogenesis.

Authors:  Janice A Nagy; Ann M Dvorak; Harold F Dvorak
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

6.  Expression of Tie-2 by human monocytes and their responses to angiopoietin-2.

Authors:  Craig Murdoch; Simon Tazzyman; Steve Webster; Claire E Lewis
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

7.  Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas.

Authors:  Ping-Pin Zheng; Wim C Hop; Theodorus M Luider; Peter A E Sillevis Smitt; Johan M Kros
Journal:  Ann Neurol       Date:  2007-07       Impact factor: 10.422

8.  Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

Authors:  Mary Anna Venneri; Michele De Palma; Maurilio Ponzoni; Ferdinando Pucci; Cristina Scielzo; Erika Zonari; Roberta Mazzieri; Claudio Doglioni; Luigi Naldini
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

9.  Gene expression profiles of endothelial progenitor cells by oligonucleotide microarray analysis.

Authors:  Souichi Furuhata; Kiyoshi Ando; Masayuki Oki; Kazunori Aoki; Shunsuke Ohnishi; Kazuhiko Aoyagi; Hiroki Sasaki; Hiromi Sakamoto; Teruhiko Yoshida; Shumpei Ohnami
Journal:  Mol Cell Biochem       Date:  2007-01-03       Impact factor: 3.842

Review 10.  Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2.

Authors:  Claire E Lewis; Michele De Palma; Luigi Naldini
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

View more
  158 in total

Review 1.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

2.  Kinins in Glioblastoma Microenvironment.

Authors:  Mona N Oliveira; Barbara Breznik; Micheli M Pillat; Ricardo L Pereira; Henning Ulrich; Tamara T Lah
Journal:  Cancer Microenviron       Date:  2019-08-16

3.  Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.

Authors:  Jean-Pierre Gagner; Yasmeen Sarfraz; Valerio Ortenzi; Fawaz M Alotaibi; Luis A Chiriboga; Awab T Tayyib; Garry J Douglas; Eric Chevalier; Barbara Romagnoli; Gérald Tuffin; Michel Schmitt; Guillaume Lemercier; Klaus Dembowsky; David Zagzag
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

4.  Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans.

Authors:  Andreas Stadlbauer; Stefan Oberndorfer; Max Zimmermann; Bertold Renner; Michael Buchfelder; Gertraud Heinz; Arnd Doerfler; Andrea Kleindienst; Karl Roessler
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-07       Impact factor: 6.200

5.  Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.

Authors:  Mai T Ngo; Brendan A C Harley
Journal:  Biomaterials       Date:  2018-06-13       Impact factor: 12.479

6.  Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Authors:  Kayla J Wolf; Joseph Chen; Jason Coombes; Manish K Aghi; Sanjay Kumar
Journal:  Nat Rev Mater       Date:  2019-08-16       Impact factor: 66.308

Review 7.  3D bioprinting of glioblastoma models.

Authors:  Carolina Parra-Cantu; Wanlu Li; Alfredo Quiñones-Hinojosa; Yu Shrike Zhang
Journal:  J 3D Print Med       Date:  2020-10-28

Review 8.  Glioblastoma stem cells: Molecular characteristics and therapeutic implications.

Authors:  Nermin Sumru Bayin; Aram Sandaldjian Modrek; Dimitris George Placantonakis
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

9.  Multi-Channel 3D Deep Feature Learning for Survival Time Prediction of Brain Tumor Patients Using Multi-Modal Neuroimages.

Authors:  Dong Nie; Junfeng Lu; Han Zhang; Ehsan Adeli; Jun Wang; Zhengda Yu; LuYan Liu; Qian Wang; Jinsong Wu; Dinggang Shen
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

10.  Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.

Authors:  Chrysovalantis Voutouri; Nathaniel D Kirkpatrick; Euiheon Chung; Fotios Mpekris; James W Baish; Lance L Munn; Dai Fukumura; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.